Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication

Gastrointestinal Endoscopy

Volumn 84, Issue 4, 2016, Pages 618-624

  Shichijo, Satoki ^a   Hirata, Yoshihiro ^a   Niikura, Ryota ^a   Hayakawa, Yoku ^a   Yamada, Atsuo ^a   Ushiku, Tetsuo ^b   Fukayama, Masashi ^b   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; COHORT ANALYSIS; CONTROLLED STUDY; ENDOSCOPIST; ENDOSCOPY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGIST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH ATROPHY; STOMACH CANCER; AGED; ATROPHY; BREATH ANALYSIS; DIAGNOSTIC IMAGING; GASTROSCOPY; HELICOBACTER INFECTION; INCIDENCE; METAPLASIA; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; STOMACH; STOMACH ANTRUM; STOMACH NEOPLASMS;

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR;

AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ATROPHY; BREATH TESTS; CLARITHROMYCIN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; LANSOPRAZOLE; MALE; METAPLASIA; METRONIDAZOLE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; PYLORIC ANTRUM; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH; STOMACH NEOPLASMS;

EID: 84975784696     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2016.03.791     Document Type: Article

References (42)

1. 1 Correa, P., Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 19:suppl 1 (1995), S37–S43.
2. 2 Correa, P., Houghton, J., Carcinogenesis of Helicobacter pylori. Gastroenterology 133 (2007), 659–672.
3. 3 Take, S., Mizuno, M., Ishiki, K., et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol 50 (2015), 638–644.
4. 4 Ford, A.C., Forman, D., Hunt, R.H., et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ, 348, 2014, g3174.
5. 5 Yoon, S.B., Park, J.M., Lim, C.H., et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 19 (2014), 243–248.
6. 6 Fukase, K., Kato, M., Kikuchi, S., et al. Group JGS. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372 (2008), 392–397.
7. 7 Ogura, K., Hirata, Y., Yanai, A., et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol 42 (2008), 279–283.
8. 8 Fuccio, L., Zagari, R.M., Eusebi, L.H., et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann Intern Med 151 (2009), 121–128.
9. 9 Yanaoka, K., Oka, M., Ohata, H., et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 125 (2009), 2697–2703.
10. 10 Wong, B.C., Lam, S.K., Wong, W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291 (2004), 187–194.
11. 11 de Vries, A.C., Kuipers, E.J., Rauws, E.A., Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn?. Am J Gastroenterol 104 (2009), 1342–1345.
12. 12 Jung, S., Park, C.H., Kim, E.H., et al. Preventing metachronous gastric lesion after endoscopic submucosal dissection through Helicobacter pylori eradication. J Gastroenterol Hepatol 30 (2015), 75–81.
13. 13 Sakitani, K., Hirata, Y., Watabe, H., et al. Gastric cancer risk according to the distribution of intestinal metaplasia and neutrophil infiltration. J Gastroenterol Hepatol 26 (2011), 1570–1575.
14. 14 Uemura, N., Okamoto, S., Yamamoto, S., et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345 (2001), 784–789.
15. 15 Shiotani, A., Iishi, H., Uedo, N., et al. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 115 (2005), 463–469.
16. 16 Hsu, P.I., Lai, K.H., Hsu, P.N., et al. Helicobacter pylori infection and the risk of gastric malignancy. Am J Gastroenterol 102 (2007), 725–730.
17. 17 de Vries, A.C., van Grieken, N.C., Looman, C.W., et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 134 (2008), 945–952.
18. 18 Cassaro, M., Rugge, M., Gutierrez, O., et al. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 95 (2000), 1431–1438.
19. 19 Shichijo, S., Hirata, Y., Sakitani, K., et al. The distribution of intestinal metaplasia as a predictor of gastric cancer development. J Gastroenterol Hepatol 30 (2015), 1260–1264.
20. 20 Shiotani, A., Uedo, N., Iishi, H., et al. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion 78 (2008), 113–119.
21. 21 Hanaoka, N., Uedo, N., Shiotani, A., et al. Autofluorescence imaging for predicting development of metachronous gastric cancer after Helicobacter pylori eradication. J Gastroenterol Hepatol 25 (2010), 1844–1849.
22. 22 Kimura, K., Takemoto, T., An endoscopic recognition of the atrophic border and its signifiance in chronic gastritis. Endoscopy 3 (1969), 87–97.
23. 23 Wu, C.Y., Kuo, K.N., Wu, M.S., et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 137 (2009), 1641–1648.e1-2.
24. 24 Rugge, M., Meggio, A., Pennelli, G., et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 56 (2007), 631–636.
25. 25 Rugge, M., de Boni, M., Pennelli, G., et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 31 (2010), 1104–1111.
26. 26 Quach, D.T., Le, H.M., Nguyen, O.T., et al. The severity of endoscopic gastric atrophy could help to predict Operative Link on Gastritis Assessment gastritis stage. J Gastroenterol Hepatol 26 (2011), 281–285.
27. 27 Wang, J., Xu, L., Shi, R., et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 83 (2011), 253–260.
28. 28 Rokkas, T., Pistiolas, D., Sechopoulos, P., et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12:Suppl 2 (2007), 32–38.
29. 29 Kodama, M., Murakami, K., Okimoto, T., et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol 47 (2012), 394–403.
30. 30 Ito, M., Haruma, K., Kamada, T., et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 16 (2002), 1449–1456.
31. 31 Kong, Y.J., Yi, H.G., Dai, J.C., et al. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol 20 (2014), 5903–5911.
32. 32 Capelle, L.G., de Vries, A.C., Haringsma, J., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 71 (2010), 1150–1158.
33. 33 den Hoed, C.M., Holster, I.L., Capelle, L.G., et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy 45 (2013), 249–256.
34. 34 Mabe, K., Takahashi, M., Oizumi, H., et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?. World J Gastroenterol 15 (2009), 4290–4297.
35. 35 Takenaka, R., Okada, H., Kato, J., et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 25 (2007), 805–812.
36. 36 Grabsch, H.I., Tan, P., Gastric cancer pathology and underlying molecular mechanisms. Dig Surg 30 (2013), 150–158.
37. 37 Mori G, Nakajima T, Asada K, et al. Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication: results of a large-scale, multicenter cohort study in Japan. Gastric Cancer. Epub 2015 Sep 29.
38. 38 Seo, J.Y., Lee, D.H., Cho, Y., et al. Eradication of Helicobacter pylori reduces metachronous gastric cancer after endoscopic resection of early gastric cancer. Hepatogastroenterology 60 (2013), 776–780.
39. 39 Tari, A., Kitadai, Y., Sumii, M., et al. Basis of decreased risk of gastric cancer in severe atrophic gastritis with eradication of Helicobacter pylori. Dig Dis Sci 52 (2007), 232–239.
40. 40 Salih, B.A., Abasiyanik, M.F., Saribasak, H., et al. A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. Dig Dis Sci 50 (2005), 1517–1522.
41. 41 Maeda, S., Amarsanaa, J., Mitsuno, Y., et al. Relationship between nuclear factor-kappaB activation and virulence factors of Helicobacter pylori in Japanese clinical isolates. J Gastroenterol Hepatol 17 (2002), 556–562.
42. 42 Ikenoue, T., Maeda, S., Ogura, K., et al. Determination of Helicobacter pylori virulence by simple gene analysis of the cag pathogenicity island. Clin Diagn Lab Immunol 8 (2001), 181–186.